Summary of Key Points Core Viewpoint - The announcement provides an update on the conversion of the company's convertible bonds into common shares, detailing the cumulative conversion amounts and the remaining unconverted bonds. Group 1: Conversion Status - As of June 30, 2025, a total of 1.719 million yuan of "Saili Convertible Bonds" has been converted into 114,799 shares, representing 0.0560% of the company's total share capital before conversion [2][9]. - The amount of unconverted "Saili Convertible Bonds" as of June 30, 2025, is 417.811 million yuan, accounting for 76.9010% of the total issuance [2][9]. - During the period from April 1, 2025, to June 30, 2025, the cumulative conversion amount was 17,000 yuan, resulting in 1,414 shares, which is 0.0007% of the total share capital before conversion [2][9]. Group 2: Convertible Bond Issuance Overview - The company issued 5.4331 million convertible bonds on August 21, 2020, with a total value of 54.331 million yuan and a maturity of six years [3][4]. - The initial coupon rates for the bonds are set at 0.50% for the first year, increasing to 3.00% by the sixth year [3]. Group 3: Conversion Price Adjustments - The initial conversion price was set at 16.98 yuan per share, which was subsequently adjusted downwards to 13.71 yuan on September 9, 2024, and further to 12.71 yuan on October 28, 2024 [5][7]. - The conversion price was later adjusted to 12.50 yuan due to share buybacks and cancellations, and then further reduced to 12.00 yuan on February 10, 2025 [8][9]. Group 4: Share Capital Changes - The total share capital increased by 1,414 shares due to the conversion of convertible bonds during the specified period [10]. - The company also experienced a reduction in share capital due to the cancellation of shares from buybacks, totaling 10,371,040 shares [11].

Group 1: Core Insights - The collaboration between Ruijin Hospital and Huawei to open-source the RuiPath pathology model marks a significant milestone in China's AI healthcare sector, promoting open collaboration and inclusive development [1] - The RuiPath model covers seven major cancer types, addressing 90% of new cancer cases in China annually, and aims to enhance diagnostic efficiency and accuracy while reducing misdiagnosis [2][3] - The AI healthcare market in China is projected to grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% [3] Group 2: Industry Trends - The AI healthcare sector is experiencing increased interest from investors, with seven AI healthcare stocks undergoing institutional research in the past month, focusing on core product development and collaborative models [4] - Companies like Sairui Medical and ZTE are integrating advanced AI technologies into their healthcare solutions, enhancing diagnostic capabilities and patient management [4][5] - The digital pathology remote diagnosis platform by Maxonic covers over 2,500 hospitals, accumulating more than 2 million digital pathology slice data, indicating a growing application of AI in tumor-assisted diagnosis [5]

Market Overview - The Shanghai Composite Index rose by 0.39% on July 1, with 20 industries experiencing gains, led by the comprehensive and pharmaceutical sectors, which increased by 2.60% and 1.80% respectively [1] - The pharmaceutical industry ranked second in terms of daily gains [1] - A total of 23 industries saw a decline, with the computer and retail sectors falling by 1.18% and 0.79% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets reached 27.907 billion yuan, with 8 industries experiencing net inflows [1] - The pharmaceutical sector had the highest net inflow of capital, amounting to 2.422 billion yuan, while the banking sector followed with a net inflow of 886 million yuan and a daily increase of 1.53% [1] - The computer industry led the net outflow, with a total of 8.395 billion yuan, followed by the power equipment sector with a net outflow of 5.163 billion yuan [1] Pharmaceutical Industry Performance - The pharmaceutical industry saw a daily increase of 1.80%, with 396 out of 474 stocks rising, including 11 stocks hitting the daily limit [2] - The top three stocks with the highest net inflow in the pharmaceutical sector were: - Sali Medical: 177 million yuan - Yipin Pharmaceutical: 168 million yuan - Guizhou Bailing: 158 million yuan [2] - The stocks with the highest net outflow included: - Hanyu Pharmaceutical: 251 million yuan - Aier Eye Hospital: 180 million yuan - Dong'e Ejiao: 79.6934 million yuan [2] Capital Inflow and Outflow Rankings - The top stocks in terms of capital inflow in the pharmaceutical sector included: - Sali Medical: +10.00%, turnover rate 29.87%, capital flow 176.9023 million yuan - Yipin Pharmaceutical: +14.72%, turnover rate 5.65%, capital flow 168.3973 million yuan - Guizhou Bailing: +10.04%, turnover rate 13.11%, capital flow 158.2571 million yuan [2] - The stocks with the highest capital outflow included: - Hanyu Pharmaceutical: +4.23%, turnover rate 18.26%, capital flow -250.5158 million yuan - Aier Eye Hospital: -1.20%, turnover rate 0.67%, capital flow -180.0828 million yuan - Dong'e Ejiao: -1.11%, turnover rate 0.94%, capital flow -79.6934 million yuan [4]

Group 1 - The innovative drug concept index rose by 3.01%, ranking third among concept sectors, with 187 stocks increasing in value [1][2] - Leading stocks included Qianyan Bio with a 20% limit up, Guizhou Bailing, Saily Medical, and Anglikang also hitting the limit up, while Kexing Pharmaceutical, Yuekang Pharmaceutical, and Shutaishen showed significant gains of 15.62%, 15.55%, and 15.34% respectively [1][2] - The stocks with the largest declines were Wantai Bio, Yaoshi Technology, and Ruilian New Materials, which fell by 1.31%, 1.27%, and 1.00% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 2.374 billion yuan, with 125 stocks receiving net inflows, and 7 stocks exceeding 100 million yuan in net inflows [2][3] - Saily Medical led the net inflow with 177 million yuan, followed by Yipin Hong with 168 million yuan, Guizhou Bailing with 158 million yuan, and Huahai Pharmaceutical with 135 million yuan [2][3] - The top three stocks by net inflow ratio were Taiankang, Saily Medical, and Guizhou Bailing, with ratios of 20.64%, 19.83%, and 17.80% respectively [3] Group 3 - The innovative drug concept's top performers included Qianyan Bio, which rose by 20.02%, and other notable gainers such as Shutaishen and Yuekang Pharmaceutical with increases of 15.34% and 15.55% respectively [4] - The trading volume and turnover rates for leading stocks were significant, with Saily Medical showing a turnover rate of 29.87% and a price increase of 10.00% [3][4] - The overall market sentiment in the innovative drug sector appears positive, with substantial capital inflows and strong performance from key players [2][3]

Core Viewpoint - The cell immunotherapy concept has seen a significant increase of 3.12%, ranking as the second highest in concept sector gains, with notable inflows of capital into 29 stocks within this sector [2][3]. Group 1: Market Performance - As of July 1, the cell immunotherapy concept experienced a 3.12% increase, with 45 stocks rising, including Yangpu Medical at a 20% limit up, and others like Saily Medical, Yuekang Pharmaceutical, Shutaishen, and Rongchang Bio showing gains of 15.55%, 15.34%, and 13.04% respectively [2][3]. - The leading decliners in this sector included *ST Biology, He’s Eye Hospital, and ST Zhongzhu, which fell by 1.36%, 0.63%, and 0.60% respectively [2]. Group 2: Capital Inflows - The cell immunotherapy sector attracted a net inflow of 472 million yuan, with 29 stocks receiving capital inflows, and 6 stocks seeing inflows exceeding 50 million yuan [3][4]. - Saily Medical led the net inflow with 177 million yuan, followed by Huahai Pharmaceutical, Betta Pharmaceutical, and Yangpu Medical with net inflows of 135 million yuan, 81.83 million yuan, and 75.87 million yuan respectively [3][4]. Group 3: Capital Flow Ratios - The top stocks by net inflow ratio included Yangpu Medical at 36.23%, Saily Medical at 19.83%, and Huahai Pharmaceutical at 14.87% [4]. - The detailed capital flow for key stocks showed Saily Medical with a 10% increase and a turnover rate of 29.87%, while Yangpu Medical had a 19.94% increase with a turnover rate of 9.99% [4][5].

Core Viewpoint - The stock of Seli Medical (603716) reached its daily limit, with a turnover rate of 29.87% and a transaction volume of 892 million yuan, indicating significant trading activity and interest from investors [1][2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange's "Dragon and Tiger List" due to its high turnover rate, with a net buying amount of 82.95 million yuan from brokerage seats [2]. - The top five brokerage seats accounted for a total transaction volume of 201 million yuan, with a buying amount of 142 million yuan and a selling amount of 59.24 million yuan, resulting in a net buying of 82.95 million yuan [2]. - The largest buying brokerage was Guotai Junan Securities, with a purchase amount of 38.21 million yuan, while the largest selling brokerage was Guoxin Securities, with a selling amount of 17.16 million yuan [2]. Historical Performance - Over the past six months, the stock has appeared on the Dragon and Tiger List 18 times, with an average price drop of 0.60% the day after being listed and an average decline of 0.31% over the following five days [3]. Capital Flow - The stock experienced a net inflow of 177 million yuan from major funds today, with a significant inflow of 176 million yuan from large orders [4]. - In the past five days, the net inflow of major funds totaled 198 million yuan [4]. Financial Performance - In the first quarter, the company reported a revenue of 287 million yuan, a year-on-year decrease of 40.75%, and a net loss of 14.32 million yuan [5].

| | | 塞力斯医疗科技集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 6 月 30 日，累计已有 171.9 万元"塞力转 债"转为公司普通股，累计转股股数为 114,799 股，占"塞力转债"转股前公司 总股本的比例为 0.0560%。 未转股可转债情况：截至 2025 年 6 月 30 日，尚未转股的"塞力转债" 金额为 41,781.1 万元，占"塞力转债"发行总量的比例为 76.9010%。 本季度转股情况："塞力转债"自 2025 年 4 月 1 日至 2025 年 6 月 30 日期间，累计转股金额为 1.7 万元，因转股形成的股份数量为 1,414 股，占"塞 力转债"转股前公司总股本的比例为 0.0007%。此期间可转债转股来源为公司新 增股份，公司股本增加 1,414 股后公司总股本为 191,018,075 股。 一、塞力转债发行上市概况 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总 ...

Market Overview - The market experienced fluctuations with mixed performance across the three major indices, with a total trading volume of 1.49 trillion [1] - The innovative drug sector saw a resurgence, with stocks like Angli康 and塞力医疗 hitting the daily limit [1] - Chip stocks continued their strong performance, with companies such as诚邦股份 and凯美特气 also reaching the daily limit [1] - Bank stocks rebounded, with建设银行 and浦发银行 reaching historical highs [1] - The military industry showed localized activity, with stocks like长城军工 and际华集团 hitting the daily limit [1] - Stablecoin concept stocks declined, with吉大正元 hitting the daily limit down [1] Key Highlights Pharmaceutical Sector - The pharmaceutical sector rebounded significantly, with昂立康 hitting the daily limit and reaching a historical high [3] - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, including increased support for R&D and inclusion in insurance directories [3][4] - Companies like阳普医疗, 塞力医疗, and山河药辅 also reached the daily limit [3] Chip Sector - The domestic chip sector remained strong, with stocks like诚邦股份, 凯美特气, and常青股份 hitting the daily limit [6] - Reports indicated that Texas Instruments is raising prices for various analog devices by 30%, with some data converters seeing price increases of 100% [6] - The semiconductor industry is entering a new growth cycle driven by AI innovations and electric vehicle developments, which is expected to boost demand for high-performance analog chips [6][8] Glass Fiber Sector - The glass fiber sector saw significant gains, with companies like宏和科技, 中材科技, and山东玻纤 hitting the daily limit [9] - Market rumors suggest that NVIDIA's upcoming Rubin cabinet may utilize quartz cloth with lower dielectric constants, enhancing its application prospects in AI servers [9][10] Military Sector - The military sector showed mixed performance, with some stocks experiencing gains while others remained stable [11] Other Sectors - The electric power, PCB, and brain science sectors showed localized activity, while solid-state batteries and blockchain concepts faced declines [11]

Group 1 - The core viewpoint of the news is the strong performance of innovative drug stocks following the release of supportive measures by the National Healthcare Security Administration and the National Health Commission to promote high-quality development of innovative drugs [1] - On July 1, innovative drug stocks saw significant gains, with Frontline Bio reaching a 20% limit up, Shuyou Shen rising over 18%, and other companies like Hot景 Bio and Rongchang Bio also experiencing substantial increases [1] - The newly issued measures include four key areas: increasing support for innovative drug research and development, encouraging commercial health insurance to expand investment in innovative drugs, enhancing drug directory admission policies, and promoting innovative drug research [1] Group 2 - Donghai Securities emphasized that innovative drugs remain the core investment direction in the pharmaceutical and biotechnology sector [2] - The National Medical Products Administration has proposed a draft to expedite the review and approval process for clinical trial applications of eligible innovative drugs to within 30 working days, further encouraging the development and market entry of innovative drugs [2] - The National Medical Products Administration is also supporting the innovation and development of high-end medical devices, introducing a series of supportive policies for cutting-edge fields such as medical robots and artificial intelligence medical devices [2]

Core Viewpoint - The A-share innovative drug sector experienced a significant surge on July 1, driven by favorable policy announcements from the National Medical Insurance Administration and the National Health Commission, which aim to support the high-quality development of innovative drugs [1][4]. Group 1: Market Performance - Frontier Biotech reached a 20% limit-up, with other companies like Guizhou BaiLing, Saily Medical, and AngliKang also hitting their limits [2]. - Notable stock performances included: - Frontier Biotech: 12.05 (+20.02%) - Kexing Pharmaceutical: 44.19 (+15.62%) - Yuyuan Pharmaceutical: 22.00 (+15.55%) - Shuyitai: 43.00 (+15.34%) - Rongchang Biotech: 68.39 (+13.04%) [3]. Group 2: Policy Support - The new measures encourage the use of medical insurance data for innovative drug research and development, enhancing collaboration among medical, insurance, and pharmaceutical sectors [4][6]. - The policy promotes the expansion of commercial health insurance investments in innovative drugs, establishing a new directory for innovative drugs that exceed basic insurance coverage [6]. - The National Medical Insurance Administration plans to streamline the application process for including drugs in both commercial and medical insurance directories, reducing the administrative burden on companies [6]. Group 3: Industry Outlook - The innovative drug sector is in a golden development phase, with over 20 first-class innovative drugs approved for market entry from January to May, marking a five-year high [7]. - Chinese pharmaceutical companies are accelerating their international expansion, with over 90 overseas licensing transactions expected in 2024, totaling over $50 billion [7]. - Significant licensing deals include: - 12.5 billion USD deal by 3SBio - 53.3 billion USD collaboration between CSPC and AstraZeneca - 42.3 billion USD agreement by Rongchang Biotech [7]. - Several biotech firms are increasing R&D investments through share placements, with funds directed towards global R&D pipelines [8]. Group 4: Investment Sentiment - Analysts agree on the sustainable growth potential of the innovative drug sector, emphasizing the "innovation + internationalization" trend as a core focus for the pharmaceutical industry [9]. - Investment opportunities are seen in the upstream pharmaceutical supply chain, advanced manufacturing, and healthcare services, with a focus on companies with strong growth potential and profitability [9].